A systematic review and meta-analysis on the therapeutic equivalence of statins: Therapeutic equivalence of statins

Weng, T.-C.; Yang, Y.-H. Kao; Lin, S.-J.; Tai, S.-H.

doi:10.1111/j.1365-2710.2009.01085.x

Cited by 345Lipoproteins and Cardiovascular HealthCancer, Lipids, and MetabolismCholesterol and Lipid Metabolism

A systematic review and meta-analysis on the therapeutic equivalence of statins: Therapeutic equivalence of statins

Open access

Weng, T.-C., Yang, Y.-H. Kao, Lin, S.-J., Tai, S.-H.·2010·Journal of Clinical Pharmacy and Therapeutics

DOI 10.1111/j.1365-2710.2009.01085.x

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Statins are the most commonly prescribed agents for hypercholesterolemia because of their efficacy and tolerability. As the number of patients in need of statin therapy continues to increase, information regarding the relative efficacy and safety of statins is required for decision-making. OBJECTIVE: This study will use systematic review to compare the efficacy and safety profiles of different statins at different doses and determine the therapeutically equivalent doses of statins to achieve a specific level of low-density lipoprotein cholesterol (LDL-C) lowering effect. METHODS: Publications of head-to-head randomized controlled trials (RCTs) of statins were retrieved from the Oregon state database (1966-2004), MEDLINE (2005-April of 2006), EMBASE (2005-April of 2006), and the Cochrane Controlled Trials Registry (up to the first quarter of 2006). The publications were evaluated with predetermined criteria by a reviewer before they were included in the review. The mean change in cholesterol level of each statin was calculated and weighted by number of subjects involved in each RCT. Where possible, meta-analysis was performed to generate pooled estimates of the cholesterol lowering effect of statins and the difference between statins. RESULTS: Seventy-five studies reporting RCTs of head-to-head comparisons on statins were included. Most studies had similar baseline characteristics, except the rosuvastatin related studies. A daily dose of atorvastatin 10 mg, fluvastatin 80 mg, lovastatin 40-80 mg, and simvastatin 20 mg could decrease LDL-C by 30-40%, and fluvastatin 40 mg, lovastatin 10-20 mg, pravastatin 20-40 mg, and simvastatin 10 mg could decrease LDL-C by 20-30%. The only two statins that could reduce LDL-C more than 40% were rosuvastatin and atorvastatin at a daily dose of 20 mg or higher. Meta-analysis indicated a statistically significant but clinically minor difference (<7%) between statins in cholesterol lowering effect. Comparisons of coronary heart disease prevention and safety could not be made because of insufficient data. CONCLUSIONS: At comparable doses, statins are therapeutically equivalent in reducing LDL-C.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1111/j.1365-2710.2009.01085.x

Cites

90 of 90 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The degree of LDL cholesterol reduction by statins is dose dependent and varies between different statins.
“The degree of LDL-C reduction is dose dependent and varies between the different statins (supplementary Figure A and supplementary Table A ). 191”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [191]
The degree of LDL cholesterol reduction by statins is dose dependent and varies between different statins.
“The degree of LDL-C reduction is dose dependent and varies between the different statins (supplementary Figure A and supplementary Table A).191”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [191]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198 · see citing works
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902 · see citing works
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938 · see citing works
Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis
Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., Brown, B. G., Ganz, P., Vogel, R. A., Crowe, T., Howard, G., Cooper, C. J., Brodie, B. R., et al. (2004) · JAMA · doi:10.1001/jama.291.9.1071 · Cited by 2,358 · see citing works
Current methods of the U.S. Preventive Services Task Force
Harris, R., Helfand, M., Woolf, S. H., Lohr, K. N., Mulrow, C. D., Teutsch, S. M., & Atkins, D. C. (2001) · American Journal of Preventive Medicine · doi:10.1016/s0749-3797(01)00261-6 · Cited by 1,720 · see citing works
Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease and stroke: systematic review and meta-analysis
Law, M. R., Wald, N. J., & Rudnicka, A. R. (2003) · BMJ · doi:10.1136/bmj.326.7404.1423 · Cited by 1,720 · see citing works
High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction<SUBTITLE>The IDEAL Study: A Randomized Controlled Trial</SUBTITLE>
Pedersen, T. R. (2005) · JAMA · doi:10.1001/jama.294.19.2437 · Cited by 1,548 · see citing works
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR**STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial)
Jones, P. H., Davidson, M. H., Stein, E. A., Bays, H. E., McKenney, J. M., Miller, E., Cain, V. A., & Blasetto, J. W. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00530-7 · Cited by 1,392 · see citing works
Comparative Dose Efficacy Study of Atorvastatin Versus Simvastatin, Pravastatin, Lovastatin, and Fluvastatin in Patients With Hypercholesterolemia (The CURVES Study) fn1fn1This study was supported by Parke-Davis, Division of Warner Lambert Company, Morris Plains, New Jersey. Manuscript received August 20, 1997; revised manuscript received and accepted November 24, 1997.
Jones, P., Kafonek, S., Laurora, I., & Hunninghake, D. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00965-x · Cited by 1,067 · see citing works
High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial
PAIVA, H., THELEN, K., COSTER, R., SMET, J., PAEPE, B., MATTILA, K., LAAKSO, J., LEHTIMAKI, T., VONBERGMANN, K., & LUTJOHANN, D. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.03.006 · Cited by 308 · see citing works
Statin-related adverse events: A meta-analysis
Silva, M. A., Swanson, A. C., Gandhi, P. J., & Tataronis, G. R. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.01.005 · Cited by 275 · see citing works
Aggressive Versus Moderate Lipid-Lowering Therapy in Hypercholesterolemic Postmenopausal Women
Raggi, P., Davidson, M. H., Callister, T. Q., Welty, F. K., Bachmann, G. A., Hecht, H. S., & Rumberger, J. A. (2005) · Circulation · doi:10.1161/circulationaha.104.512681 · Cited by 271 · see citing works
An Assessment of Statin Safety by Muscle Experts
Thompson, P. D., Clarkson, P. M., & Rosenson, R. S. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.013 · Cited by 263 · see citing works
Comparison of One-Year Efficacy and Safety of Atorvastatin Versus Lovastatin in Primary Hypercholesterolemia
Davidson, M. H., McKenney, J. M., Stein, E. A., Schrott, H. G., Bakker-Arkema, R. G., Fayyad, R. S., & Black, D. M. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00174-4 · Cited by 233 · see citing works
Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia
Davidson, M. H., Ma, P., Stein, E. A., Gotto, A. M., Raza, A. A., Chitra, R., & Hutchinson, H. G. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)02226-3 · Cited by 230 · see citing works
A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients witb hypercholesterolemia
Dart, A. M., Jerums, G., Nicholson, G. C., dʼEmden, M. C., Hamilton‐Craig, I. R., Tallis, G. A., Best, J. D., West, M., SULLIVAN, D. R., Braes, P., et al. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00280-4 · Cited by 186 · see citing works
Treating patients with documented atherosclerosis to national cholesterol education program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin
Brown, A. S., Bakker-Arkema, R. G., Yellen, L. G., et al. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00300-3 · Cited by 181 · see citing works
Achieving and maintaining national cholesterol education program low-density lipoprotein cholesterol goals with five statins
Andrews, T. C., Ballantyne, C. M., Hsia, J. A., & Kramer, J. H. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00799-9 · Cited by 178 · see citing works
Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia
OLSSON, A. G., Istad, H., Luurila, O. J., Ose, L., Stender, S., Tuomilehto, J. O., Wiklund, O., Southworth, H., Pears, J. S., & Wilpshaar, J. W. (2002) · American Heart Journal · doi:10.1067/mhj.2002.128049 · Cited by 177 · see citing works
The Safety of Rosuvastatin as Used in Common Clinical Practice
Alsheikh-Ali, A. A. A., Ambrose, M. S., Kuvin, J. T., & Karas, R. H. (2005) · Circulation · doi:10.1161/circulationaha.105.555482 · Cited by 167 · see citing works
Effects of switching statins on achievement of lipid goals: measuring effective reductions in cholesterol using rosuvastatin therapy (MERCURY I) study
Schuster, H., Barter, P. J., Stender, S., Cheung, R. C., Bonnet, J., Morrell, J. M., Watkins, C. L., Kallend, D. G., & Raza, A. A. (2004) · American Heart Journal · doi:10.1016/j.ahj.2003.10.004 · Cited by 160 · see citing works
Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects
Schaefer, E. J., McNamara, J. R., Tayler, T., Daly, J. A., Gleason, J. L., SEMAN, L. J., Ferrari, A., & Rubenstein, J. J. (2003) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2003.09.008 · Cited by 157 · see citing works
Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: A randomized, double-blind, 52-week trial
Brown, W. V., Bays, H. E., Hassman, D. R., McKenney, J. M., Chitra, R., Hutchinson, H. G., & Miller, E. (2002) · American Heart Journal · doi:10.1067/mhj.2002.129312 · Cited by 157 · see citing works
Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups
Blasetto, J. W., Stein, E. A., Brown, W. V., Chitra, R., & Raza, A. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00003-1 · Cited by 144 · see citing works
Statin Safety: Lessons from New Drug Applications for Marketed Statins
Jacobson, T. A. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.009 · Cited by 144 · see citing works
Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease
Schneck, D. W., Knopp, R. H., Ballantyne, C. M., McPherson, R., Chitra, R., & Simonson, S. G. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02994-6 · Cited by 140 · see citing works
Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia.
Bertolini, S., Bon, G., Campbell, L., Farnier, M., Langan, J., Mahla, G., Pauciullo, P., Sirtori, C., Egros, F., Fayyad, R., et al. (1997) · Atherosclerosis · doi:10.1016/s0021-9150(96)06052-2 · Cited by 140 · see citing works
Rosuvastatin Demonstrates Greater Reduction of Low-Density Lipoprotein Cholesterol Compared with Pravastatin and Simvastatin in Hypercholesterolaemic Patients: A Randomized, Double-Blind Study
Paoletti, R., Fahmy, M. I., Mahla, G., Mizan, J., & Southworth, H. (2001) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/174182670100800608 · Cited by 129 · see citing works
Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I
Crouse, J. R., Frohlich, J. J., Ose, L., Mercuri, M. F., & Tobert, J. A. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00153-8 · Cited by 125 · see citing works
A COmparative study with rosuvastatin in subjects with METabolic Syndrome: results of the COMETS study†
Stalenhoef, A. F. H., Ballantyne, C. M., Sarti, C., Murín, J., Tonstad, S., Rose, H., & Wilpshaar, W. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi482 · Cited by 116 · see citing works
Statin safety: an appraisal from the adverse event reporting system
Davidson, M. H., Clark, J. A., Glass, L. M., & Kanumalla, A. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.008 · Cited by 113 · see citing works
Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention
Zhou, Z., Rahme, E., & Pilote, L. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.04.003 · Cited by 109 · see citing works
A Comparison of Simvastatin and Atorvastatin up to Maximal Recommended Doses in a Large Multicenter Randomized Clinical Trial
Illingworth, D. R., Crouse, J. R., Hunninghake, D. B., Davidson, M., Escobar, I. D., Stalenhoef, A. F. H., Paragh, G., Ma, P. T. S., Liu, M., Melino, M. R., et al. (2001) · Current Medical Research and Opinion · doi:10.1185/03007990152005351 · Cited by 90 · see citing works
Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia
Daubresse, J. (1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90601-8 · Cited by 80 · see citing works
Cholesterol‐lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes – CORALL study
Wolffenbuttel, B. H. R., Franken, A. A. M., Vincent, H. H., & THE DUTCH CORALL STUDY GROUP (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01499.x · Cited by 79 · see citing works
Comparison of Efficacy and Safety of Rosuvastatin Versus Atorvastatin in African-American Patients in a Six-Week Trial
Ferdinand, K. C., Clark, L. T., Watson, K. E., et al. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.08.026 · Cited by 76 · see citing works
Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study
Berne, C., Siewert-Delle, A., & the URANUS study investigators (2005) · Cardiovascular Diabetology · doi:10.1186/1475-2840-4-7 · Cited by 73 · see citing works
Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease
Karalis, D. G., Ross, A. M., Vacari, R. M., Zarren, H. S., & Scott, R. C. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)02337-2 · Cited by 72 · see citing works
Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: Results of the Comparative HDL Efficacy and Safety Study (CHESS)
Ballantyne, C. M., Blazing, M. A., Hunninghake, D. B., Davidson, M. H., Yuan, Ž., DeLucca, P. T., Ramsey, K. E., Hustad, C. M., & Palmisano, J. J. (2003) · American Heart Journal · doi:10.1016/s0002-8703(03)00440-x · Cited by 72 · see citing works
Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease.
Hunninghake, D. B., Bakker-Arkema, R. G., Wigand, J., et al. (1998) · PubMed · Cited by 71 · see citing works
Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels
Kastelein, J. J. P., Isaacsohn, J. L., Ose, L., Hunninghake, D. B., Frohlich, J. J., Davidson, M. H., Habib, R., Dujovne, C. A., Crouse, J. R., Liu, M., et al. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)00942-5 · Cited by 69 · see citing works
Comparative efficacy study of atorvastatin vs. simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia
Gentile, S., Turco, S., Guarino, G., Sasso, F. C., Amodio, M., Magliano, P. L., Salvatore, T., Corigliano, G., Agrusta, M., SIMONE, G. D., et al. (2000) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2000.00106.x · Cited by 66 · see citing works
Comparison of efficacy and safety of atorvastatin (10 mg) with simvastatin (10 mg) at six weeks
Insull, W., Kafonek, S. D., Goldner, D., et al. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)01430-2 · Cited by 62 · see citing works
LDL‐C/HDL‐C ratio in subjects with cardiovascular disease and a low HDL‐C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study
Jukema, J. W., Liem, A. H., Dunselman, P. H. J. M., van der Sloot, J. A. P., Lok, D. J. A., & Zwinderman, A. H. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x74952 · Cited by 61 · see citing works
Twelve-week, multicenter, randomized, open-label comparisonof the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study
Strandberg, T. E., Feely, J., & Sigurdsson, E. L. (2004) · Clinical Therapeutics · doi:10.1016/j.clinthera.2004.11.015 · Cited by 56 · see citing works
Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial
Schwartz, G. G., Bolognese, M. A., Tremblay, B., Caplan, R. J., Hutchinson, H. G., Raza, A., & Cressman, M. D. (2004) · American Heart Journal · doi:10.1016/j.ahj.2004.01.020 · Cited by 55 · see citing works
A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia
The Lovastatin Pravastatin Study Group∗ (1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90829-2 · Cited by 54 · see citing works
A Comparison of Simvastatin and Atorvastatin up to Maximal Recommended Doses in a Large Multicenter Randomized Clinical Trial
Illingworth, D. R., Crouse, J. R., Hunninghake, D. B., et al. (2001) · Current Medical Research and Opinion · doi:10.1185/0300799039117026 · Cited by 54 · see citing works
Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect
Zhou, Z. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.1041403 · Cited by 53 · see citing works
Safety of low-density lipoprotein cholesterol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE Trial)
März, W., Wollschläger, H., Klein, G., Neiß, A., & Wehling, M. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00183-6 · Cited by 49 · see citing works
Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. The Simvastatin and Lovastatin Multicenter Study Participants.
Farmer, J. A., Washington, L. C., Jones, P. H., et al. (1993) · PubMed · Cited by 44 · see citing works
A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: The treat-to-target (3T) study
OLSSON, A. G. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)90015-4 · Cited by 43 · see citing works
Efficacy of Atorvastatin Compared With Simvastatin in Patients With Hypercholesterolemia
Farnier, M., Portal, J.-J., & Maigret, P. (2000) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424840000500104 · Cited by 38 · see citing works
Comparative Efficacy and Tolerability of 5 and 10 mg Simvastatin and 10 mg Pravastatin in Moderate Primary Hypercholesterolemia
Steinhagen‐Thiessen, E. (2008) · Cardiology · doi:10.1159/000176682 · Cited by 38 · see citing works
Effect of statins on LDL particle size in patients with familial combined hyperlipidemia: a comparison between atorvastatin and pravastatin
Sirtori, C. R., Calabresi, L., Pisciotta, L., Cattin, L., Pauciullo, P., Montagnani, M., Manzato, E., Bon, G. B., & Fellin, R. (2005) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2004.08.001 · Cited by 37 · see citing works
Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia
Paragh, G., Törőcsik, D., Seres, I., Harangi, M., Illyés, L., Balogh, Z., & Kovacs, P. L. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125004394 · Cited by 37 · see citing works
Efficacy and tolerability of simvastatin 20 mg vs pravastatin 20 mg in patients with primary hypercholesterolemia. European Study Group.
Lambrecht, L., & Malini, P. L. (1993) · PubMed · Cited by 37 · see citing works
Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia
JACOTOT, B., Benghozi, R., Pfister, P., HOLMES, D., & ON, B. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(05)80018-9 · Cited by 36 · see citing works
Simvastatin versus pravastatin: efficacy and tolerability in patients with primary hypercholesterolemia.
Malini, P. L., Ambrosioni, E., DIVITIIS, O. D., et al. (1991) · PubMed · Cited by 34 · see citing works
Comparison of the efficacy and tolerability of simvastatin and atorvastatin in the treatment of hypercholesterolemia
Recto, C. S., Acosta, S., & Dobs, A. S. (2000) · Clinical Cardiology · doi:10.1002/clc.4960230910 · Cited by 33 · see citing works
The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL‐C Value – an Evaluation of Rosuvastatin therapY compared with atorvastatin
Fonseca, F. A. H., Ruiz, Á. J., Cardona-Muñóz, E. G., Silva, J. M., Fuenmayor, N. T., Marotti, M., & for the DISCOVERY PENTA investigators (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x56529 · Cited by 32 · see citing works
Comparison of the short-term efficacy and tolerability of lovastatin and pravastatin in the management of primary hypercholesterolemia.
McPherson, R., Bédard, J., Connelly, P. W., et al. (1992) · PubMed · Cited by 31 · see citing works
Therapeutic Controversies; Lack of Therapeutic Interchangeability of HMG-CoA Reductase Inhibitors
Chong, P. H. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1c116 · Cited by 30 · see citing works
Double-Blind Comparison of the Efficacy and Tolerability of Simvastatin and Fluvastatin in Patients with Primary Hypercholesterolaemia
Ose, L., & Scott, R. S. (1995) · Clinical Drug Investigation · doi:10.2165/00044011-199510030-00001 · Cited by 29 · see citing works
The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: A comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia
Saklamaz, A., Çömlekçi, A., Artmann, A. T., Uysal, S., Ceylan, C., Alacacıoğlu, A., & Yeşil, S. (2005) · Metabolism · doi:10.1016/j.metabol.2004.12.012 · Cited by 28 · see citing works
Efficacy and tolerability of simvastatin and pravastatin in patients with primary hypercholesterolemia (multicountry comparative study)
The European Study Group∗ (1992) · The American Journal of Cardiology · doi:10.1016/0002-9149(92)90762-n · Cited by 27 · see citing works
Treatment of primary hypercholesterolaemia. Short‐term efficacy and safety of increasing doses of simvastatin and pravastatin: a double‐blind comparative study
Stalenhoef, A. F. H., Lansberg, P. J., Kroon, A. A., et al. (1993) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1993.tb00708.x · Cited by 24 · see citing works
Hemostatic Effects of Atorvastatin versus Simvastatin
Kadıköylü, G., Yükselen, V., Yavaşoğlu, İ., & Bolaman, Z. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1c189 · Cited by 22 · see citing works
Comparison of the impact of atorvastatin and simvastatin on apoA-I kinetics in men
Mauger, J., Couture, P., Paradis, M., & Lamarche, B. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.06.022 · Cited by 22 · see citing works
Effects of low doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol levels in patients with hypercholesterolemia
Branchi, A., Fiorenza, A. M., Torri, A., et al. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80073-4 · Cited by 22 · see citing works
Achieving lipid goals in real life: the Dutch DISCOVERY Study
Bots, A. F. E., Kastelein, J. J. P., & on behalf of the discovery netherlands investigators (2005) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2005.00708.x · Cited by 22 · see citing works
A multicenter, randomized, double-blind clinical trial comparing the low-density lipoprotein cholesterol-lowering ability of lovastatin 10, 20, and 40 mg/d with fluvastatin 20 and 40 mg/d
Davidson, M. H., Palmisano, J. J., Wilson, H. M., Liss, C. L., & Dicklin, M. R. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80330-2 · Cited by 21 · see citing works
Relation between perfusion defects on stress technetium-99m sestamibi SPECT scintigraphy and the location of a subsequent acute myocardial infarction
Miller, G. L., Herman, S. D., Heller, G. V., et al. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(96)00221-4 · Cited by 20 · see citing works
Comparison of the effects on quality of life and of the efficacy and tolerability of lovastatin versus pravastatin
Weir, M. R., Berger, M. L., Weeks, M. L., Liss, C. L., & Santanello, N. C. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)89340-x · Cited by 19 · see citing works
Meeting National Cholesterol Education Goals in Clinical Practice—A Comparison of Lovastatin and Fluvastatin in Primary Prevention
Nash, D. T. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(96)00659-5 · Cited by 19 · see citing works
Efficacy and safety of a new cholesterol synthesis inhibitor, atorvastatin, in comparison with simvastatin and pravastatin, in subjects with hypercholesterolemia
Wolffenbuttel, B. H. R. (1998) · The Netherlands Journal of Medicine · doi:10.1016/s0300-2977(97)00092-2 · Cited by 16 · see citing works
Treating hypercholesterolaemia with HMG CoA reductase inhibitors: a direct comparison of simvastatin and pravastatin
Lintott, C. J., Sutherland, W. H. F., Scott, R. S., et al. (1993) · Australian and New Zealand Journal of Medicine · doi:10.1111/j.1445-5994.1993.tb01439.x · Cited by 16 · see citing works
Efficacy and Tolerability of Fluvastatin and Simvastatin in Hypercholesterolaemic Patients
Schulte, K.-L., & Beil, S. (1996) · Clinical Drug Investigation · doi:10.2165/00044011-199612030-00001 · Cited by 15 · see citing works
Comparative Study of the Efficacy and Tolerability of Simvastatin and Pravastatin in Patients with Primary Hypercholesterolaemia
Douste-Blazy, P., Ribeiro, V. G., Seed, M., et al. (1993) · Clinical Drug Investigation · doi:10.1007/bf03259612 · Cited by 15 · see citing works
Simvastatin compared to fluvastatin in the reduction of serum lipids and apolipoproteins in patients with ischaemic heart disease and moderate hypercholesterolaemia.
Sigurðsson, G., Haraldsdottir, S. O., Melberg, T. H., et al. (1998) · PubMed · Cited by 13 · see citing works
A Comparison of the Tolerability and Efficacy of Lovastatin 20 mg and Fluvastatin 20 mg in the Treatment of Primary Hypercholesterolemia
Berger, M. L., Wilson, H. M., & Liss, C. L. (1996) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424849600100203 · Cited by 12 · see citing works
Efficacy and safety of atorvastatin and pravastatin in patients with hypercholesterolemia
Assmann, G., Hüwel, D., Schussmann, K., Smilde, J. G., Kösling, M., Withagen, A. J. A. M., Wunderlich, J., Stoel, I., van Dormaal, J. J., Neuss, J., et al. (1999) · European Journal of Internal Medicine · doi:10.1016/s0953-6205(99)00011-4 · Cited by 11 · see citing works
Comparison of the short term efficacy and tolerability of lovastatin and simvastatin in the management of primary hypercholesterolemia.
Frohlich, J., Ld, B., Blank, D. W., et al. (1993) · PubMed · Cited by 11 · see citing works
Effects of fluvastatin slow-release (xl 80 mg) versus simvastatin (20 mg) on the lipid triad in patients with type 2 diabetes
Bevilacqua, M. T., Righini, V., Barrella, M., Vago, T., Chebat, E., & Dominguez, L. J. (2005) · Advances in Therapy · doi:10.1007/bf02849947 · Cited by 10 · see citing works
Comparative efficacy and tolerability of low-dose pravastatin versus lovastatin in patients with hypercholesterolemia
Strauss, W., Lapsley, D. P., & Gaziano, J. M. (1999) · American Heart Journal · doi:10.1016/s0002-8703(99)70492-8 · Cited by 8 · see citing works
Hydroxymethylglutaryl-coenzyme A Reductase Inhibitors (statins) VHA Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel
Kelley, C., Helfand, M., Good, C. B., & Ganz, M. L. (2002) · Cited by 8 · see citing works
Hypertension control: results from the Diabetes Care Program of Nova Scotia registry and impact of changing clinical practice guidelines
Russell, C., Dunbar, P., Salisbury, S. R., et al. (2005) · Cardiovascular Diabetology · doi:10.1186/1475-2840-4-11 · Cited by 7 · see citing works
Additional Efficacy of Milligram-Equivalent Doses of Atorvastatin over Simvastatin
van Dam, M., Basart, D. C. G., Janus, C., Zwertbroek, R., Spierenburg, H. A. M., Werner, H. A., Bredero, A. C., Lansberg, P. J., Jonker, C. J., Trip, M. D., et al. (2000) · Clinical Drug Investigation · doi:10.2165/00044011-200019050-00002 · Cited by 7 · see citing works
Crossover Trial of Simvastatin Versus Pravastatin in Patients with Primary Hypercholesterolemia
Sasaki, S., Sawada, S., Nakata, T., et al. (1997) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199707000-00021 · Cited by 6 · see citing works
A comparative study of atorvastatin and simvastatin as monotherapy for mixed hyperlipidaemia in Type 2 diabetic patients
Chan, W., Ko, G. T. C., Yeung, M. W., et al. (2004) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2004.06.007 · Cited by 6 · see citing works

Flagged first, then by citations

Research works printed but not linked: 9

Chong PH (2002) Lack of therapeutic interchange- ability of HMG-CoA reductase inhibitors. Annals of Pharmacotherapy, 36, 1907-1917.
Jones PH, Davidson MH, Stein EA et al. (2003) Comparison of the efficacy and safety of rosuvastatin vs. atorvastatin, simvastatin, and pravastatin across doses (STELLAR* trial). American Journal of Cardiol- ogy, 92, 152-160.
Dart A, Jerums G, Nicholson G, et al. (1997) A multicenter, double-blind, one-year study compar- ing safety and efficacy of atorvastatin vs. simvas- tatin in patients with hypercholesterolemia. The American Journal of Cardiology, 80, 39-44.
E18. Kadikoylu G, Yukselen V, Yavasoglu I, Bolaman Z (2003) Hemostatic effects of atorvastatin vs. sim- vastatin. The Annals of pharmacotherapy, 37, 478-484.
E22. Brown AS, Bakker-Arkema RG, Yellen L, et al. (1998) Treating patients with documented athero- sclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein parative study). The European Study Group. American Journal of Cardiology, 70, 1281-1286.
E55. Jones PH, Davidson MH, Stein EA, et al. (2003) Comparison of the efficacy and safety of rosuvas- tatin vs. atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). The American Journal of Cardiology, 92, 152-160.
E60. Cannon CP, Braunwald E, McCabe CH, et al. (2004) Intensive vs. moderate lipid lowering with statins after acute coronary syndromes. The New England Journal of Medicine, 350, 1495-1504.
E66. Pedersen TR, Faergeman O, Kastelein JJP, et al. (2005) High-dose atorvastatin vs. usual-dose sim- vastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized con- trolled trial. Journal of the American Medical Associa- tion, 294, 2437-2445.
E75. Middleton A, Fuat A (2006) Achieving lipid goals in real life: the DISCOVERY-UK study. British Journal of Cardiology, 13, 72-76.

Sorted by citations

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162 · see citing works
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582 · see citing works
National Institutes of Health Approaches to Dissemination and Implementation Science: Current and Future Directions
Glasgow, R. E., Vinson, C., Chambers, D., Khoury, M. J., Kaplan, R. M., & Hunter, C. (2012) · American Journal of Public Health · doi:10.2105/ajph.2012.300755 · Cited by 762 · see citing works
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706 · see citing works
Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study
Ramos, R., Comas-Cufí, M., Martí-Lluch, R., Balló, E., Ponjoan, A., Alves-Cabratosa, L., Blanch, J., Marrugat, J., Elosua, R., Grau, M., et al. (2018) · BMJ · doi:10.1136/bmj.k3359 · Cited by 215 · see citing works
Targeting inflammation to reduce cardiovascular disease risk: A realistic clinical prospect?
Welsh, P., Grassia, G., Botha, S., Sattar, N., & Maffia, P. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13818 · Cited by 164 · see citing works
Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: results from the Dyslipidemia International Study II
Gitt, A. K., Lautsch, D., Ferrières, J., De Ferrari, G. M., Vyas, A., Baxter, C. A., Bash, L. D., Ashton, V., Horack, M., Almahmeed, W., et al. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.08.013 · Cited by 148 · see citing works
Which interventions offer best value for money in primary prevention of cardiovascular disease
Cobiac, L. J., Magnus, A., Lim, S., Barendregt, J. J., Carter, R., & Vos, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041842 · Cited by 97 · see citing works
A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: Review of the clinical evidence
Barrios, V., Escobar, C., Cicero, A. F. G., Burke, D., Fasching, P., Banach, M., & Bruckert, E. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2016.10.003 · Cited by 96 · see citing works
Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment
Pisciotta, L., Bellocchio, A., & Bertolini, S. (2012) · Lipids in Health and Disease · doi:10.1186/1476-511x-11-123 · Cited by 79 · see citing works
Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy
Wiklund, O., Pirazzi, C., & Romeo, S. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0397-8 · Cited by 45 · see citing works
Comparison of low-dose statin versus low-dose statin + Armolipid Plus in high-intensity statin-intolerant patients with a previous coronary event and percutaneous coronary intervention (ADHERENCE Trial)
Marazzi, G., Campolongo, G., Pelliccia, F., Quattrino, S., Vitale, C., Cacciotti, L., Massaro, R., Volterrani, M., & Rosano, G. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.06.015 · Cited by 36 · see citing works
Longitudinal evaluation of efficacy, safety and nutritional status during one-year treatment with the duodenal-jejunal bypass liner
Riedel, N., Laubner, K., Lautenbach, A., Schön, G., Schlensak, M., Stengel, R., Eberl, T., Dederichs, F., Aberle, J., & Seufert, J. (2018) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2018.02.029 · Cited by 15 · see citing works

Fluvastatin vs pravastatin in treating hyperlipidemia
Xiao, H. (2001) · Chinese Journal of New Drugs and Clinical Remedies
A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia
Saitō, Y., Yamada, N., Teramoto, T., Itakura, H., Yoshiya, H. A. T. A., Nakaya, N., Mabuchi, H., Tushima, M., Sasaki, J., & Ogawa, N. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(01)00712-2 · Cited by 114 · see citing works
Concentrations of Pravastatin and Lovastatin in Cerebrospinal Fluid in Healthy Subjects
Botti, R. E., Triscari, J. M., Pan, H. Y., & Zayat, J. (1991) · Clinical Neuropharmacology · doi:10.1097/00002826-199106000-00010 · Cited by 127 · see citing works
Replacing lovastatin with pravastatin: Effect on serum lipids and costs
Korman, L. B., & Borysiuk, L. (1995) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/52.10.1078 · Cited by 22 · see citing works
A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia
The Lovastatin Pravastatin Study Group∗ (1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90829-2 · Cited by 54 · see citing works

Authors: Weng, T.-C., Yang, Y.-H. K., Lin, S.-J., & Tai, S.-H.
Affiliations: National Cheng Kung University (TW)
University of Illinois Chicago (US)
National Cheng Kung University Hospital (TW)
ORCID: Yang, Y.-H. Kao
Lin, S.-J.
Venue: Journal of Clinical Pharmacy and Therapeutics
Publisher: Wiley
Published: 2009-08-14
Volume: 35
Issue: 2
Pages: 139-151
ISSN: 0269-4727 (ISSN-L)
DOI: 10.1111/j.1365-2710.2009.01085.x
OpenAlex: W1735246829
Cited by: 345
References: 90
Citations by year: 2026: 11 · 2025: 6 · 2024: 10 · 2023: 19 · 2022: 20 · 2021: 16 · 2020: 11 · 2019: 19 · 2018: 39 · 2017: 33 · 2016: 28 · 2015: 22 · 2014: 21 · 2013: 38 · 2012: 26
FWCI: 2.72
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: doi.wiley.com/10.1002/tdm_license_1.1 (tdm)
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Journal of Clinical Pharmacy and Therapeutics (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
Keywords: statins, therapeutic equivalence, LDL cholesterol lowering, hypercholesterolemia, atorvastatin, fluvastatin, lovastatin, simvastatin, pravastatin, rosuvastatin, statin dose comparison, statin safety
MeSH terms: Anticholesteremic Agents, Dose-Response Relationship, Drug, Humans, Hypercholesterolemia, Cholesterol, LDL, Therapeutic Equivalency, Randomized Controlled Trials as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A systematic review and meta-analysis on the therapeutic equivalence of statins: Therapeutic equivalence of statins

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks